Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

By the end of this month, two pharmaceutical firms are set to receive a decision on their drug approval applications from the U.S. Food and Drug Ad...

FDA Calendar: These Are the Upcoming FDA Drug Approvals 

In a report released on November 14, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $297.00. The...

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Alkerme...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Alkermes (ALKS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $250.00. According ...

Morgan Stanley Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

An announcement from Ascendis Pharma ( ($ASND) ) is now available. Ascendis Pharma reported strong financial results for the third quarter of 2025,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$210.49	+0.45%	600.98K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$210.49	+0.4%	600.98K
3
4
5
6

ASND

ASND

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel